OpenURL Connection Search

Select item for more details and to access through your institution.

Flow Cytometry-Based Measurement of Antibodies Specific for Cell Surface-Expressed Folded SARS-CoV-2 Receptor-Binding Domains.
Published in:
Vaccines, 2024, v. 12, n. 4, p. 377, doi. 10.3390/vaccines12040377
By:
- Sehgal, Al Nasar Ahmed;
- Safran, Jera;
- Kratzer, Bernhard;
- Gattinger, Pia;
- Stieger, Robert B.;
- Musiejovsky, Laszlo;
- Trapin, Doris;
- Ettel, Paul;
- Körmöczi, Ulrike;
- Rottal, Arno;
- Borochova, Kristina;
- Dorofeeva, Yulia;
- Tulaeva, Inna;
- Weber, Milena;
- Grabmeier-Pfistershammer, Katharina;
- Perkmann, Thomas;
- Wiedermann, Ursula;
- Valenta, Rudolf;
- Pickl, Winfried F.
Publication type:
Article
The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024.
Published in:
International Archives of Allergy & Immunology, 2024, v. 185, n. 3, p. 286, doi. 10.1159/000533677
By:
- Sehgal, Al Nasar Ahmed;
- Tauber, Peter A.;
- Stieger, Robert B.;
- Kratzer, Bernhard;
- Pickl, Winfried F.
Publication type:
Article
Differential decline of SARS‐CoV‐2‐specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID‐19.
Published in:
Allergy, 2024, v. 79, n. 9, p. 2482, doi. 10.1111/all.16210
By:
- Kratzer, Bernhard;
- Gattinger, Pia;
- Trapin, Doris;
- Ettel, Paul;
- Körmöczi, Ulrike;
- Rottal, Arno;
- Stieger, Robert B.;
- Sehgal, Al Nasar Ahmed;
- Feichter, Melanie;
- Borochova, Kristina;
- Tulaeva, Inna;
- Grabmeier‐Pfistershammer, Katharina;
- Tauber, Peter A.;
- Perkmann, Thomas;
- Fae, Ingrid;
- Wenda, Sabine;
- Kundi, Michael;
- Fischer, Gottfried F.;
- Valenta, Rudolf;
- Pickl, Winfried F.
Publication type:
Article

Found: 3

Flow Cytometry-Based Measurement of Antibodies Specific for Cell Surface-Expressed Folded SARS-CoV-2 Receptor-Binding Domains.

The T-Cell Growth Factor Interleukin-2, Which Is Occasionally Targeted by Autoantibodies, Qualifies as Drug for the Treatment of Allergy, Autoimmunity, and Cancer: Collegium Internationale Allergologicum (CIA) Update 2024.

Differential decline of SARS‐CoV‐2‐specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID‐19.